770 related articles for article (PubMed ID: 16968347)
1. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
[TBL] [Abstract][Full Text] [Related]
2. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
[TBL] [Abstract][Full Text] [Related]
3. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
4. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
5. Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence.
Colagiuri B; Morley K; Boakes R; Haber P
Psychother Psychosom; 2009; 78(3):167-71. PubMed ID: 19270472
[TBL] [Abstract][Full Text] [Related]
6. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
[TBL] [Abstract][Full Text] [Related]
7. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Rösner S; Leucht S; Lehert P; Soyka M
J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
[TBL] [Abstract][Full Text] [Related]
8. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
9. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial.
Morley KC; Teesson M; Sannibale C; Baillie A; Haber PS
Alcohol Alcohol; 2010; 45(6):520-6. PubMed ID: 20952764
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
Snyder JL; Bowers TG
Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Kiefer F; Helwig H; Tarnaske T; Otte C; Jahn H; Wiedemann K
Eur Addict Res; 2005; 11(2):83-91. PubMed ID: 15785069
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
13. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence.
Laaksonen E; Koski-Jännes A; Salaspuro M; Ahtinen H; Alho H
Alcohol Alcohol; 2008; 43(1):53-61. PubMed ID: 17965444
[TBL] [Abstract][Full Text] [Related]
14. Comparing topiramate with naltrexone in the treatment of alcohol dependence.
Baltieri DA; Daró FR; Ribeiro PL; de Andrade AG
Addiction; 2008 Dec; 103(12):2035-44. PubMed ID: 18855810
[TBL] [Abstract][Full Text] [Related]
15. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Namkoong K; Lee BO; Lee PG; Choi MJ; Lee E
Alcohol Alcohol; 2003; 38(2):135-41. PubMed ID: 12634260
[TBL] [Abstract][Full Text] [Related]
16. Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone.
Kiefer F; Jiménez-Arriero MA; Klein O; Diehl A; Rubio G
Addict Biol; 2008 Mar; 13(1):124-9. PubMed ID: 17573782
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological treatment of alcohol dependence: a review of the evidence.
Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial.
Guardia J; Caso C; Arias F; Gual A; Sanahuja J; Ramírez M; Mengual I; Gonzalvo B; Segura L; Trujols J; Casas M
Alcohol Clin Exp Res; 2002 Sep; 26(9):1381-7. PubMed ID: 12351933
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.
Berger L; Fisher M; Brondino M; Bohn M; Gwyther R; Longo L; Beier N; Ford A; Greco J; Garbutt JC
Alcohol Clin Exp Res; 2013 Apr; 37(4):668-74. PubMed ID: 23134193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
